Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open label phase II multicenter clinical trial to evaluate safety during accelerated dose escalation of an allergoid birch pollen preparation in patients with IgE mediated allergic rhinitis or rhinoconjunctivitis with or without controlled bronchial asthma

Trial Profile

Open label phase II multicenter clinical trial to evaluate safety during accelerated dose escalation of an allergoid birch pollen preparation in patients with IgE mediated allergic rhinitis or rhinoconjunctivitis with or without controlled bronchial asthma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Asthma; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Adverse reactions
  • Acronyms ASTOR
  • Sponsors Allergopharma

Most Recent Events

  • 26 Aug 2017 Status changed from recruiting to completed.
  • 13 Jan 2017 There has been a protocol amendment where the planned number of patients changed from 360 to 120 and the patient age for inclusion has changed from 2-64 to 18-64 .
  • 07 Jul 2016 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top